Share price · AZN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
See what was announced around each unusual move
Research flags the days this stock moved far more than its sector fund, lists the news, filings and earnings dated around each one, and shows how much of its unusual movement fell on each asset's announcements.
Assets
(78 total)
| Target & Modality | |||
|---|---|---|---|
albuterol / budesonide(Airsupra) | Approved | Beta-2 adrenergic receptor · Glucocorticoid receptor · Glucocorticoid receptor / Beta-2 adrenergic receptorCombination | Asthma |
| Approved | AromataseSmall molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Approved | Type I interferon receptor · Type I interferon receptor subunit 1 (IFNAR1)Monoclonal antibody | Systemic Lupus Erythematosus | |
Baxdrostat(Baxfendy) | Approved | Aldosterone synthase (CYP11B2)Small molecule | HypertensionHeart FailureChronic Kidney Disease |
Benralizumab(Fasenra) | Approved | IL-5 receptor alpha · IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC) · IL-5 receptor alpha (IL5RA) on eosinophils/basophilsMonoclonal antibody | Chronic Obstructive Pulmonary DiseaseAsthma |
Budesonide(Pulmicort) | Approved | Glucocorticoid receptor agonistSmall molecule | Asthma |
| Approved | Glucocorticoid receptor; Beta-2 adrenergic receptorCombination | Asthma | |
Budesonide/glycopyrrolate/formoterol fumarate(Breztri Aerosphere) | Approved | Glucocorticoid receptor; Muscarinic M3; Beta-2 adrenergicSmall molecule | Chronic Obstructive Pulmonary DiseaseAsthma |
| Approved | AKT (inhibitor)Small molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
Dapagliflozin(Farxiga / Forxiga) | Approved | SGLT2Small molecule | Type 2 DiabetesHeart FailureChronic Kidney DiseaseAtherosclerotic Cardiovascular Disease |
| Approved | TROP2Antibody–drug conjugate | Non-Small Cell Lung CancerBreast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Approved | PD-L1Monoclonal antibody | Non-Small Cell Lung Cancer | |
Fulvestrant(Faslodex) | Approved | Estrogen receptorSmall molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer |
| Approved | EGFRSmall molecule | Non-Small Cell Lung Cancer | |
Glycopyrrolate/formoterol fumarate(Bevespi Aerosphere) | Approved | Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptorSmall molecule | Chronic Obstructive Pulmonary Disease |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Unlock insider transactions
Research includes SEC Form 4 insider transactions: filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Unlock institutional holders
Research includes quarterly SEC 13F institutional ownership: top holders, aggregate positions and quarter-over-quarter context.